-
公开(公告)号：WO2022120037A1
公开(公告)日：2022-06-09
申请号：PCT/US2021/061595
申请日：2021-12-02
Applicant: HOFFMAN-LA ROCHE INC. , F. HOFFMAN-LA ROCHE AG
Inventor： NOVOSEL, Jelena
IPC: G06V10/80
Abstract: Methods and systems for predicting visual acuity response are provided. The methods and systems utilize one or more of a first input that includes two-dimensional imaging data and a second input that includes three-dimensional imaging data. A visual acuity response (VAR) output is predicted, via a neural network system, using the first input and/or the second input. The VAR output comprises a predicted change in visual acuity of a subject undergoing a treatment.
-
公开(公告)号：WO2022094629A1
公开(公告)日：2022-05-05
申请号：PCT/US2021/072166
申请日：2021-11-01
Applicant: GENENTECH, INC. , F. HOFFMANN-LA ROCHE AG , HOFFMAN-LA ROCHE INC. , VENTANA MEDICAL SYSTEMS, INC. , NIE, Yao
Inventor： LI, Xiao , NGUYEN, Trung Kien , GAIRE, Fabien , KLAIMAN, Eldad , BEN-SHAUL, Ido , GILDENBLAT, Jacob , HADAR, Ofir Etz
Abstract: Systems and methods relate to predicting disease progression by processing digital pathology images using neural networks. A digital pathology image that depicts a specimen stained with one or more stains is accessed. The specimen may have been collected from a subject. A set of patches are defined for the digital pathology image. Each patch of the set of patches depicts a portion of the digital pathology image. For each patch of the set of patches and using an attention-score neural network, an attention score is generated. The attention-score neural network may have been trained using a loss function that penalized attention-score variability across patches in training digital pathology images labeled to indicate no or low subsequent disease progression. Using a result-prediction neural network and the attention scores, a result is generated that represents a prediction of whether or an extent to which a disease of the subject will progress.
-
公开(公告)号：WO2022036129A1
公开(公告)日：2022-02-17
申请号：PCT/US2021/045792
申请日：2021-08-12
Applicant: F. HOFFMANN-LA ROCHE AG , HOFFMAN-LA ROCHE INC.
Inventor： MANFRINI, Marianna
Abstract: The present invention concerns methods for treating multiple sclerosis (MS) in a patient by using the anti-CD20 antibody ocrelizumab, and an article of manufacture with instructions for such use. In particular it relates to a dosage regimen of ocrelizumab wherein the initial and second dose is of 1,2 grams for patients of less than 75 kg weight or of 1,8 grams for patients of 75 kg or more at an interval of about 6 months.
-
公开(公告)号：WO2007022102A3
公开(公告)日：2007-02-22
申请号：PCT/US2006/031682
申请日：2006-08-14
Applicant: GENENTECH, INC. , HOFFMAN-LA ROCHE, INC. , F. HOFFMAN-LA ROCHE, AG , ZHOU, Aihe , RAWSON, Thomas, E. , SAFINA, Brian , DOTSON, Jennafer , ALIAGAS-MARTIN, Ignacio , HALLADAY, Jason , LIANG, Jun , RUETH, Matthias , ZHU, Bing-Yan , BROOKFIELD, Frederick , PRIME, Michael , ZHANG, Birong , LI, Jun, M.
Inventor： RAWSON, Thomas, E. , SAFINA, Brian , DOTSON, Jennafer , ALIAGAS-MARTIN, Ignacio , HALLADAY, Jason , LIANG, Jun , RUETH, Matthias , ZHU, Bing-Yan , BROOKFIELD, Frederick , PRIME, Michael , ZHANG, Birong , LI, Jun, M.
IPC: C07D487/04 , C07D491/04 , A61K31/4155 , A61P35/00
Abstract: The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula: (I) wherein A, X, Y, Z, Ra, Rb, Rc, R 1 , R 2 , R 3 and m are defined herein.
-
公开(公告)号：WO2021154755A1
公开(公告)日：2021-08-05
申请号：PCT/US2021/015130
申请日：2021-01-26
Applicant: GENENTECH, INC. , F. HOFFMANN-LA ROCHE AG , HOFFMAN-LA ROCHE INC.
Inventor： ZHENG, Kai , POROCK, Edward , KHURANA, Mahesh , WISE, Geoffrey Colin , PESINO, Lorenzo Myles Paredes , HATCH, Michelle , YOHE, Stefan , BONDI, Raffaella Claudia
Abstract: An apparatus and method for direct drug infusion from a vial to a patient are provided. A movable hanger label is provided to adhere to and support the vial to facilitate direct infusion of a drug, such as one or more pharmaceuticals, biopharmaceuticals, and/or biologics, from the vial to the patient. Additionally, a process is provided in which the drug, contained in the vial with the movable hanger label, may be directly infused through a primed infusion line with a rapid infusion rate. A saline flush is incorporated at the end of the administration to flush the infusion line, resulting in a reduced amount of the drug remaining in the line.
-
Patent Agency Ranking
公开(公告)号：WO2018175954A1
公开(公告)日：2018-09-27
申请号：PCT/US2018/024127
申请日：2018-03-23
Applicant: F. HOFFMANN-LA ROCHE AG , HOFFMAN-LA ROCHE INC. , GENENTECH, INC.
Inventor： ANGELAUD, Remy , BACHMANN, Stephan , BEYELER, Andreas , CARRERA, Diane , FISCHER, Rolf , GUILLEMONT-PLASS, Maud , HOU, Haiyun , IDING, Hans , KRAFT, Anne Katrin , MANNS, Andreas , MEIER, Roland , NIEDERMANN, Karin, Monika , OLBRICH, Martin , PIECHOWICZ, Katarzyna , REGE, Pankaj , REMARCHUK, Travis, Paul , SIROIS, Lauren , ST-JEAN, Frederic , XU, Jie
IPC: C07D487/04
CPC classification number: C07D487/04
Abstract: Presently provided is a method of making a compound of the Formula (I) wherein X is halogen, which is useful for modulating the activity of indoleamine 2,3-dioxygenase (IDO) and treating diseases and conditions in which the inhibition of IDO mediated immunosuppression is beneficial.
-
公开(公告)号：WO2013174873A1
公开(公告)日：2013-11-28
申请号：PCT/EP2013/060529
申请日：2013-05-22
Applicant: F. HOFFMANN-LA ROCHE AG , HOFFMAN-LA ROCHE INC.
Inventor： CASTOLDI, Raffaella , HAAS, Alexander , KLEIN, Christian , SCHAEFER, Wolfgang , SUSTMANN, Claudio
IPC: C07K16/46 , C07K16/32 , C07K16/28 , C07K16/22 , A61K39/395
CPC classification number: C07K16/32 , A61K39/39558 , A61K2039/505 , C07K16/22 , C07K16/2863 , C07K16/468 , C07K2317/31 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/66 , C07K2317/92 , C07K2319/70
Abstract: The present invention relates to bivalent, multispecific antibodies, especially bivalent, trispecific antibodies which bind to human HER1, human HER2, and human HER3, their manufacture and use.
Abstract translation: 本发明涉及结合人HER1，人HER2和人HER3的二价，多特异性抗体，特别是二价三特异性抗体，其制备和用途。
-
公开(公告)号：WO2003068940A2
公开(公告)日：2003-08-21
申请号：PCT/US2003/004594
申请日：2003-02-14
Applicant: CURAGEN CORPORATION , HOFFMAN LA-ROCHE INC. , JACKSON, Amanda , OOI, Chean, Eng , LEWIN, David, A. , CUTHILL, Scott
Inventor： JACKSON, Amanda , OOI, Chean, Eng , LEWIN, David, A. , CUTHILL, Scott
IPC: C12N
CPC classification number: C07K14/005 , A61K38/00 , C07K2319/00 , C12N2710/20022 , G01N33/532 , G01N33/56983 , G01N33/57442 , G01N2333/025 , G01N2500/00 , G01N2500/02
Abstract: The invention provides complexes of at least two polypeptides, and methods of using the same. Purified complexes of two polypeptides are provided, including chimeric complexes, and chimeric polypeptides and complexes thereof are also provided, as are nucleic acids encoding chimeric polypeptides and vectors and cells containing the same. Also provided are methods of identifying agents that disrupt polypeptide complexes, methods of identifying complex or polypeptide in a sample, and for removing the same, methods of determining altered expression of a polypeptide in a subject, and methods of treating/preventing disorders involving altered levels of complex or polypeptide.
Abstract translation: 本发明提供至少两种多肽的复合物及其使用方法。 还提供了两种多肽的纯化复合物，包括嵌合复合物，以及嵌合多肽及其复合物，编码嵌合多肽的核酸和含有该多肽的载体和细胞也是如此。 还提供了鉴定破坏多肽复合物的试剂的方法，鉴定样品中复合物或多肽的方法，以及用于除去样品的方法，确定受试者中多肽表达改变的方法，以及治疗/预防涉及改变水平的病症的方法 的复合物或多肽。
-
公开(公告)号：WO2003068940A3
公开(公告)日：2003-08-21
申请号：PCT/US2003/004594
申请日：2003-02-14
Applicant: CURAGEN CORPORATION , HOFFMAN LA-ROCHE INC. , JACKSON, Amanda , OOI, Chean, Eng , LEWIN, David, A. , CUTHILL, Scott
Inventor： JACKSON, Amanda , OOI, Chean, Eng , LEWIN, David, A. , CUTHILL, Scott
IPC: A61K39/00
Abstract: The invention provides complexes of at least two polypeptides, and methods of using the same. Purified complexes of two polypeptides are provided, including chimeric complexes, and chimeric polypeptides and complexes thereof are also provided, as are nucleic acids encoding chimeric polypeptides and vectors and cells containing the same. Also provided are methods of identifying agents that disrupt polypeptide complexes, methods of identifying complex or polypeptide in a sample, and for removing the same, methods of determining altered expression of a polypeptide in a subject, and methods of treating/preventing disorders involving altered levels of complex or polypeptide.
-
公开(公告)号：WO2022066788A1
公开(公告)日：2022-03-31
申请号：PCT/US2021/051579
申请日：2021-09-22
Applicant: GENENTECH, INC. , F. HOFFMAN-LA ROCHE AG , HOFFMAN-LA ROCHE INC.
Inventor： LI, Yvonna Yun , STEFFEN, Verena Lisa , BENMANSOUR, Fethallah , FRIESENHAHN, Michel James , HASKOVA, Zdenka
Abstract: A method and system for managing a treatment of a subject diagnosed with a macular edema condition. Subject data for a subject is received. The subject data comprises best corrected visual acuity (BCVA) data for the subject. An input for a computational model is generated using the subject data. An injection frequency for the treatment of the subject diagnosed with the macular edema condition is predicted, via the computational model, based on the input.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.024 seconds)
